title: Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.
abstract: Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that is responsible for considerable epidemics worldwide and recently emerged in the Americas in 2013. CHIKV may cause long-lasting arthralgia after acute infection. With currently no licensed vaccines or antivirals, the design of effective therapies to prevent or treat CHIKV infection is of utmost importance and will be facilitated by increased understanding of the dynamics of chikungunya. In this article, monoclonal antibodies against CHIKV as viable prophylactic and therapeutic agents will be discussed.
authors.affiliation: Office of Global Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
authors.forename: April M
authors.initials: AM
authors.lastname: Clayton
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D057134:Antibodies, Neutralizing / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000627:therapeutic use*; D018771:Arthralgia / Q000276:immunology / Q000628:therapy / Q000821:virology; D065632:Chikungunya Fever / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy* / Q000821:virology; D002646:Chikungunya virus / Q000276:immunology*; D006801:Humans; D007116:Immunization, Passive
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral
keywords: alphaviruses; chikungunya; monoclonal antibodies; therapies